New hope for Tough-to-Treat blood cancer: major trial tests promising drug combo
Disease control
Not yet recruiting
This study is testing whether adding a new immunotherapy drug called sugemalimab to standard chemotherapy works better than chemotherapy alone for adults with a rare and aggressive type of blood cancer (NK/T-cell lymphoma) that has returned or not responded to prior treatment. Th…
Phase: PHASE3 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC